[
  {
    "ts": null,
    "headline": "Pfizer Declares First-Quarter 2025 Dividend",
    "summary": "NEW YORK, December 12, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer.",
    "url": "https://finnhub.io/api/news?id=db16ecf1fec3c54396f50049ecfbc0b86b4641a48193ee41a98d9de8101278f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734042300,
      "headline": "Pfizer Declares First-Quarter 2025 Dividend",
      "id": 131948643,
      "image": "https://media.zenfs.com/en/business-wire.com/199d97f61444abb6d215808088242480",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 12, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer.",
      "url": "https://finnhub.io/api/news?id=db16ecf1fec3c54396f50049ecfbc0b86b4641a48193ee41a98d9de8101278f9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Boost Quarter Dividend by 2.4% to 43 Cents",
    "summary": "By Paul Ziobro Pfizer on Thursday said it will raise its quarterly dividend by 2.4%. The New York-based drug company on Thursday said its board increased its cash dividend to 43 cents a share...",
    "url": "https://finnhub.io/api/news?id=c75493420fd0bf400ded791cf457ac031b536dfee43f82431b460386b3b5cb7b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734026114,
      "headline": "Pfizer Boost Quarter Dividend by 2.4% to 43 Cents",
      "id": 131949266,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Paul Ziobro Pfizer on Thursday said it will raise its quarterly dividend by 2.4%. The New York-based drug company on Thursday said its board increased its cash dividend to 43 cents a share...",
      "url": "https://finnhub.io/api/news?id=c75493420fd0bf400ded791cf457ac031b536dfee43f82431b460386b3b5cb7b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Boost Quarterly Dividend by 2.4% to 43c",
    "summary": "Pfizer Boost Quarterly Dividend by 2.4% to 43c",
    "url": "https://finnhub.io/api/news?id=abe629b49781fad69a237e1c692676d3832bd95890d1ffbbbccd753b73169e4b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734025140,
      "headline": "Pfizer Boost Quarterly Dividend by 2.4% to 43c",
      "id": 132066920,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Boost Quarterly Dividend by 2.4% to 43c",
      "url": "https://finnhub.io/api/news?id=abe629b49781fad69a237e1c692676d3832bd95890d1ffbbbccd753b73169e4b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients",
    "summary": "On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (H",
    "url": "https://finnhub.io/api/news?id=3dac41729a7883beb55637744809f2aa2a20afedfbcd0c1a967e430da0cc0245",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734024950,
      "headline": "Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients",
      "id": 131948645,
      "image": "https://media.zenfs.com/en/Benzinga/869190d1d87d06fdc7ba4bcfa65b2164",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (H",
      "url": "https://finnhub.io/api/news?id=3dac41729a7883beb55637744809f2aa2a20afedfbcd0c1a967e430da0cc0245"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Amazon Explore Collaboration with RFK Jr. on Climate and Health Crisis",
    "summary": "Kennedy, Pfizer, and Amazon Target Chronic Diseases Amid Climate Threats",
    "url": "https://finnhub.io/api/news?id=491ae3ad32f0cc391be9d11dec7a8e083ed2be5c403c333b25756b192305f9de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734019095,
      "headline": "Pfizer and Amazon Explore Collaboration with RFK Jr. on Climate and Health Crisis",
      "id": 131948649,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/1f614dc8aade043fa2491082626588e5",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Kennedy, Pfizer, and Amazon Target Chronic Diseases Amid Climate Threats",
      "url": "https://finnhub.io/api/news?id=491ae3ad32f0cc391be9d11dec7a8e083ed2be5c403c333b25756b192305f9de"
    }
  },
  {
    "ts": null,
    "headline": "CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal",
    "summary": "Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.",
    "url": "https://finnhub.io/api/news?id=cd23adf3dd9985ad2892692e3678e6857d585ba223815ba54d8c88e36400309d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734017460,
      "headline": "CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal",
      "id": 131932010,
      "image": "https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.",
      "url": "https://finnhub.io/api/news?id=cd23adf3dd9985ad2892692e3678e6857d585ba223815ba54d8c88e36400309d"
    }
  },
  {
    "ts": null,
    "headline": "Are Pfizer Inc.'s (NYSE:PFE) Mixed Financials Driving The Negative Sentiment?",
    "summary": "It is hard to get excited after looking at Pfizer's (NYSE:PFE) recent performance, when its stock has declined 13% over...",
    "url": "https://finnhub.io/api/news?id=f85260e8cb397d3b214e782ff076aa0d8f3de99672f2003d3f0c0991c91f19bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734012020,
      "headline": "Are Pfizer Inc.'s (NYSE:PFE) Mixed Financials Driving The Negative Sentiment?",
      "id": 131948653,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8f018d189c2c443014c49845310ae091",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It is hard to get excited after looking at Pfizer's (NYSE:PFE) recent performance, when its stock has declined 13% over...",
      "url": "https://finnhub.io/api/news?id=f85260e8cb397d3b214e782ff076aa0d8f3de99672f2003d3f0c0991c91f19bc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer",
    "summary": "NEW YORK, December 12, 2024--Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE® (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epider",
    "url": "https://finnhub.io/api/news?id=13a0d118a1fcc21bce03bc30bf60310b1ffcae0792318cead802366602781f75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734009300,
      "headline": "Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer",
      "id": 131948655,
      "image": "https://media.zenfs.com/en/business-wire.com/83fdfe68473e89eb3064a6d236924639",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 12, 2024--Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE® (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epider",
      "url": "https://finnhub.io/api/news?id=13a0d118a1fcc21bce03bc30bf60310b1ffcae0792318cead802366602781f75"
    }
  },
  {
    "ts": null,
    "headline": "How Pfizer management outplayed activist investor Starboard",
    "summary": "The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.",
    "url": "https://finnhub.io/api/news?id=41091b334518861e1214d9ce7344acaa09d506dd65fc29aad95098869e87c9bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733990400,
      "headline": "How Pfizer management outplayed activist investor Starboard",
      "id": 131948657,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Bourla.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.",
      "url": "https://finnhub.io/api/news?id=41091b334518861e1214d9ce7344acaa09d506dd65fc29aad95098869e87c9bc"
    }
  }
]